浙江时迈药业有限公司 Alternatives & Competitors
12 companies similar to 浙江时迈药业有限公司 — 以患者和临床需求为己任
Companies similar to 浙江时迈药业有限公司
KangaBio
Pioneering novel therapies to enhance treatment effectiveness and reduce side effects for...
Shasqi
Targeting cancer with click chemistry
Rexahn Pharmaceuticals
TARGETING DIFFICULT TO TREAT CANCERS
LeadInvent Pharma Inc.
Harnessing the power of nanotechnology and laser for eradicating brain cancer
Rival Readout
Competing with 浙江时迈药业有限公司? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Strike Pharma AB
Harnessing personalized medicine to target tumors and protect healthy cells, delivering co...
TRIO Pharmaceuticals, Inc.
Outsmart Cancer
KORTUC INC.
Revolutionzing Cancer Radiotherapy by the cutting edge technology from Japan.
Semafore Pharmaceuticals
Pioneering the future of cancer treatment with innovative PI3K inhibitors.
ALCELI
Safe, Effective, Affordable Proton Beam Therapy
About 浙江时迈药业有限公司
Centrymed is a biotechnology startup founded in 2017 that focuses on innovative solutions in tumor treatment. The company's slogan "Innovative solutions in tumor treatment leveraging a proprietary dual-antibody platform to address drug stability and minimize side effects" encapsulates its mission. Centrymed has develop...
Tumor Treatment, Dual-antibody Platform, Drug Stability, Side Effects Minimization, Intellectual Property, Drug Effectiveness, Toxicity, Antibody Medications, Centrymed, Pharmaceuticals, Cancer Therapy, Innovation, Medical Technology
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around 浙江时迈药业有限公司: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at 浙江时迈药业有限公司 on 12 Sep 2024. The 12 companies listed here were last checked between 25 Jul 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.